# Mark R. Litzow

Source: https://onco.cc/people/mark-litzow/  
OnCo record `mark-litzow` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.

## Summary

Mark Litzow is Professor of Medicine at Mayo Clinic, Chair of the ECOG-ACRIN Leukemia Committee and Study Chair of E1910. A haematologist specialising in acute lymphoblastic leukaemia, immunotherapy and transplant, he chaired ECOG-ACRIN E1910, the trial that put blinatumomab consolidation into frontline treatment for adults in MRD-negative remission and led to a 2024 label change. His papers report blinatumomab for MRD-negative acute lymphoblastic leukaemia in adults in the New England Journal of Medicine and allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukaemia in Blood. His work centres on CD19 and CD3 directed therapy in B-ALL.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910
- Specialisms: Acute lymphoblastic leukaemia; Immunotherapy; Transplant

## Sources

- Mayo Clinic research faculty: https://www.mayo.edu/research/faculty
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Mark%20R.%20Litzow

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- drugs: [Blinatumomab](https://onco.cc/drugs/blinatumomab/)
- companies: [ECOG-ACRIN Cancer Research Group](https://onco.cc/companies/ecog-acrin/)
- institutions: [Mayo Clinic](https://onco.cc/institutions/mayo-clinic/)
- trials: [ECOG-ACRIN E1910](https://onco.cc/trials/e1910/)
- key papers: [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/mark-litzow.json